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RESEARCH ARTICLE
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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of Kaposi’s sar-
coma (KS). It is endemic in a number of sub-Saharan African countries with infection rate of
>50%. The high prevalence of HIV-1 coupled with late presentation of advanced cancer
staging make KS the leading cancer in the region with poor prognosis and high mortality.
Disease markers and cellular functions associated with KS tumorigenesis remain ill-defined.
Several studies have attempted to investigate changes of the gene profile with in vitro infec-
tion of monoculture models, which are not likely to reflect the cellular complexity of the in
vivo lesion environment. Our approach is to characterize and compare the gene expression
profile in KS lesions versus non-cancer tissues from the same individual. Such comparisons
could identify pathways critical for KS formation and maintenance. This is the first study that
utilized high throughput RNA-seq to characterize the viral and cellular transcriptome in
tumor and non-cancer biopsies of African epidemic KS patients. These patients were
treated anti-retroviral therapy with undetectable HIV-1 plasma viral load. We found remark-
able variability in the viral transcriptome among these patients, with viral latency and
immune modulation genes most abundantly expressed. The presence of KSHV also signifi-
cantly affected the cellular transcriptome profile. Specifically, genes involved in lipid and glu-
cose metabolism disorder pathways were substantially affected. Moreover, infiltration of
immune cells into the tumor did not prevent KS formation, suggesting some functional defi-
cits of these cells. Lastly, we found only minimal overlaps between our in vivo cellular tran-
scriptome dataset with those from in vitro studies, reflecting the limitation of in vitro models
in representing tumor lesions. These findings could lead to the identification of diagnostic
and therapeutic markers for KS, and will provide bases for further mechanistic studies on
the functions of both viral and cellular genes that are involved.
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Author summary
Kaposi’s sarcoma-associated herpesvirus (KSHV) is endemic in sub-Saharan Africa and
cause Kaposi’s sarcoma (KS). KS is one of the most common cancer among HIV-1
patients in this region. Despite anti-retroviral treatment, prognosis for KS is poor with
high mortality often due to presentation of late cancer stage. In order to identify biomark-
ers or therapeutic targets against KS, a better understanding of the viral and cellular genes
expression/transcriptome in the tumor will be necessary. We used RNA-seq, a highly effi-
cient method to sequence transcriptome, to characterize and compare the viral and cellu-
lar transcriptome in tumor and non-cancer tissues from KS patients. We found that viral
genes involved in latency and immune modulation are most commonly expressed among
KS patients. Additionally, cellular genes involved in lipid and glucose metabolism disorder
pathways are significantly affected by the presence of KSHV. Despite the detection of
immune cells in the tumor, it did not prevent the tumor progression, suggesting some
level of immune cell dysfunctions in KS patients. Lastly, we found limited overlap of our
data, derived from actual KS biopsy, with other cell culture models, suggesting that the
complexity of tumor is difficult to be reflected in cell line models.
Introduction
Kaposi’s sarcoma (KS) is a multi-focal pleomorphic, highly vascularized tumor that is one of
the AIDS defining illnesses. KS mostly manifest as cutaneous lesions, but it can also be
detected in the oral mucosa, lymph nodes and all visceral organ systems. There are four types
of KS: iatrogenic, classic, endemic and epidemic/AIDS-related KS [1–4]. Endemic and epi-
demic KS are the most common forms in sub-Sahara Africa. Endemic KS occurs in HIV-1
negative African patients of both genders. The presentation in both genders at varying ages dif-
ferentiates this form of KS from classical KS found mostly in elderly Mediterranean men. Epi-
demic KS occurs in patients who are HIV-1 positive, and along with iatrogenic KS, which
results from chemical immunosuppression, highlights the role of immune dysregulation in KS
development. Depending on the location of lesions, KS patients may display signs and symp-
toms such as nausea, vomiting, dysphagia and dyspnea. Cutaneous lesions may also disfigure
and lead to social stigma for KS patients [5, 6]. The prognosis of KS patients in sub-Sahara
Africa is generally poor, often due to delayed diagnosis and late initiation of treatment [7].
Even after receiving anti-retroviral drugs therapy (ART), the mortality of epidemic KS patient
is often high due to advanced KS disease staging, simultaneous advanced HIV-1 diagnosis and
both HIV-1 and KS-immune reconstitution inflammatory syndromes [8].
The etiologic agent associated with KS is the Kaposi’s sarcoma-associated herpesvirus
(KSHV) or human herpesvirus type 8 (HHV-8) which is a member of the gamma-herpesviri-
dae. It is an enveloped virus with a double-stranded viral DNA of approximately 170-Kb. The
KSHV genome encodes more than 80 genes that are expressed in a regulated transcriptional
program that promotes latency with very limited viral expression, or supports lytic replication
with the production of progeny virions. The cellular tropism of KSHV includes epithelial,
endothelial, B cells, and more recently has been expanded to include neurons [9–17]. Depend-
ing on the host cell environment encountered upon infection, the virus may establish latency
and only express latency related genes such as latency-associated nuclear antigen (LANA).
LANA expression helps KSHV prevent programmed cell death and circumvent host immune
surveillance [18–22]. During reactivation, the entire KSHV genetic repertoire is expressed
enabling virus replication and propagation.
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KSHV has a high seroprevalence in sub-Sahara Africa, where over 50% of the population
has detectable anti-KSHV antibodies [23]. The virus can be transmitted by saliva and sexual
routes [24–28]. In addition to KS, KSHV is also the etiological agent of other lymphoprolifera-
tive disorders such as multicentric Castleman’s disease (MCD) and primary effusion lym-
phoma (PEL) [15, 29, 30]. KS can be an opportunistic malignancy commonly presenting in
untreated HIV-1 infected patients [31]. Due to the high HIV-1 prevalence in sub-Sahara Africa
countries such as Zambia and Tanzania, KS is the leading cancer in men and the third leading
cancer in women in Africa [32, 33]. In contrast to the drastic reduction of KS in resource-rich
regions, widespread implementation of ART in sub-Saharan Africa, has only modestly reduced
KS incidence among the resource-limited countries of the region [34, 35].
There are currently no existing targeted immunotherapies against viral or host proteins
in KS, and there is no vaccine against KSHV infection. Indeed the correlates of KS develop-
ment or protection are ill-defined. A more complete understanding of changes in host and
viral gene expression in KS lesions compared with non-tumor tissues could provide insights
into the interactions between KSHV and the host that drive development of KS. Moreover,
it would allow exploration for any potential biomarkers that are unique to KS neoplastic
cells. These biomarkers could make early detection of KS possible and perhaps help to elimi-
nate one of the major malignancies in sub-Saharan Africa. In addition, gene expression pro-
files of KS lesions may also lead to identification of pathways required for KS neoplasia.
Inhibition of such essential pathways could potentially provide therapeutic benefit for KS
patients.
RNA-Seq is an extremely high density, unbiased sequencing technique that allows high-
throughput assessment of total cellular transcription. It exhibits a broader dynamic range and
specificity than microarray analyses [36, 37]. Thus RNA-Seq is an ideal tools for defining the
gene expression profiles or transcriptome of KS lesions. RNA-Seq has been utilized in tran-
scriptomic analysis of various forms of cancers to identify pathways that could provide poten-
tial targets for future diagnosis or therapy [38, 39]. However, only a limited number of in vitro
studies on KSHV infected cell lines or infected monocultures of specific lineages of cells, have
utilized either RNA-Seq or microarray for transcriptomic analyses [40–47]. In the current
study, epidemic KS lesion biopsies were collected from Zambia and Tanzania for comparative
transcriptomic analysis using RNA-Seq. Ipsilateral or contralateral sampling of normal tissues
from the same KS patients provided for direct intra-subject comparison of gene expression
profiles. We found that KSHV has significantly impacted the cellular gene expression that
were involved in the lipid and glucose metabolism disorder pathways. To our knowledge, this
is the first study to utilize RNA-Seq to provide unbiased gene expression profile directly from
KS lesions in comparison to that of non-neoplastic tissue from the same subject. Our study
provides unique insights into the interactions between KSHV and the host and may point to
previously unrecognized pathways in KS pathogenesis.
Materials and methods
Ethics statement
Permission to conduct this study was obtained from Tanzania National Institute for Medical
Research, Ocean Road Cancer Institute Review Board, University of Zambia Biomedical
Research Ethics Committee and the Institutional Review Board of the University of
Nebraska-Lincoln. Written informed consents were obtained from all study participants and
the study did not interfere with the routine clinical care of the participants as per institute’s
guidelines.
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Sample collection and processing
Histologically confirmed epidemic KS patients ( 18 years old) were recruited from University
Teaching Hospital (UTH), Zambia and Ocean Road Cancer Institute (ORCI), Tanzania.
Whole blood was collected from each patient and separated into plasma and mononuclear
cells using Lymphoprep according to the manufacturer’s protocol (Stemcell technologies, Mas-
sachusetts, USA).
A 4 mm cylindrical single-use punch was used to collect biopsy samples from a representa-
tive KS lesion and a second identical punch biopsy was collected from an uninvolved ipsilateral
/contralateral site on the same individual. The collected tissues were treated overnight in RNA-
Later (Ambion) to facilitate subsequent DNA/RNA extraction. RNALater was removed prior
to freezing at -80˚C.
Determination of HIV-1 status and plasma viral load
The HIV-1 status for the Tanzanian KS patient was determined using the Tanzania HIV Rapid
Test Algorithm. Zambian KS patients’ HIV-1 status was determined using the Alere Deter-
mine HIV-1/2 Ag/Ab Combo test. The HIV-1 serostatus of all subjects was re-confirmed at
the University of Nebraska-Lincoln with the HIV-1-2.0 First Response kit (Premier Medical
Corporation Limited, Daman, India).
HIV-1 viral RNA was extracted from plasma using the QIAamp viral RNA mini kit follow-
ing the manufacturer’s protocol (Qiagen, Hildren, Germany). HIV-1 plasma viral load was
quantified by RT-PCR (QuantStudio 3, Applied Biosystems, Carlsbad, CA) using oligonucleo-
tides HIV-1 LTR forward primer [5’-GCCTCAATAAAGCTTGCCTTGA-3’], reverse primer
[5’- GGGCGCCACTGCTAGAGA-3’] and probe [5’-FAM-CCAGAGTCACACAACAGACG
GGCACA-BHQ_1–3’] under the following reaction conditions: 50˚C for 15 min, 95˚C for 2
min; 45 cycles at 95˚C for 15 sec and 60˚C for 30 sec.
Detection of KSHV DNA in plasma
KSHV DNA was extracted from the patient plasma with QIAmp DNA mini kit (Qiagen, Hil-
den, Germany) according to manufacturer’s protocol. The extracted DNA was confirmed to
be PCR negative for β-actin to demonstrate the absence of cellular DNA contamination. To
detect the presence of KSHV DNA, nested-PCR for KSHV ORF26 was performed on the
extracted DNA (1st round PCR primers: forward [5’-AGCCGAAAGATTCCACCAT-3’] and
reverse [5’-TCCGTGTTGTCTACGTCCAG-3’], 2nd round PCR primers: Forward [5’-CGAA
TCCAACGGATTTGACCTC-3’] and reverse [5’-CCCATAAATGACACATTGGTGGTA-3’])
using the following conditions: 95˚C for 5 min; 35 cycles at 95˚C for 30 sec, 58˚C for 30 sec,
72˚C for 30 sec; 72˚C for 7 min. The final PCR product was analyzed on a 1% TAE agarose gel
versus a KSHV ORF26 DNA positive amplification product at 173 base pairs. Genomic DNA
from the KSHV chronically infected BC3 cell line was used as positive control.
Quantification of KSHV DNA load in lesion tissues
Fresh frozen biopsies from KS lesions were homogenized by cryo-cracking with liquid nitro-
gen. Genomic DNA was extracted from the homogenized sample using Puregene genomic
DNA purification kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol. To
quantify the KSHV DNA load from the lesion, the extracted DNA was analyzed by real-time
PCR against KSHV ORF26 with the 2nd round PCR primers set listed above and the following
probe [5’-FAM-CCATGGTCGTGCCGCACGCA-BHQ_1–3’]. A plasmid encoding KSHV
ORF26 was used to create a standard curve to compare patient DNA amplification signals.
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The number of cells analyzed was quantified by comparing patient DNAs to a standard curve
produced by real-time PCR for the β-globin gene. Genomic DNA from the human cell line
8E5 was used as a standard. All reactions were performed in triplicate under the following con-
ditions: 50˚C for 2 min, 95˚C for 10 min; 40 cycles of 95˚C for 15 sec, and 60˚C for 1 min.
RNA library preparation and RNA-Seq
Fresh frozen biopsies from KS lesions and ipsilateral/contralateral normal sites were homoge-
nized by cryo-cracking in liquid nitrogen using a mortar and pestle. Briefly, the mortar and
pestle were cleaned and chilled in a metal tray with liquid nitrogen. The sample was transferred
from -80˚C storage on dry ice into the pre-chilled mortar, followed by pulverize and homoge-
nize using the pre-chilled pestle. The homogenized sample is then transferred into a 2-ml
Eppendorf tube by a pre-chilled spatula for genomic RNA extraction.
Genomic RNA was extracted from the homogenized sample with miRNeasy mini kit with
on-column DNase I treatment according to the manufacturer’s protocol (Qiagen, Hilden, Ger-
many). Concentration of the extracted RNA was measured with a Qubit fluorometer using the
Qubit RNA Broad-Range kit (Invitrogen, Waltham, MA). Quality of the extracted RNA was
assessed by an Agilent Bio-Analyzer system (Agilent Technologies, Santa Clara, CA) for frag-
ment analysis. By measuring the 18s and 28s rRNA peaks within the electrophoretic trace, the
RNA Integrity Number (RIN) was calculated to determine the level of RNA integrity. Only
samples with an RIN>4.9 were used for library preparation and RNA-Seq. Library prepara-
tion was performed using the TruSeq™ RNA Library Prep Kit v2, and RNA-Seq data were col-
lected using an Illumina HiSeq2500 in single-read, 50 bp Rapid Run mode at the University of
Nebraska Medical Center DNA Sequencing Core.
RNA-Seq data analysis
The RNA-seq data was aligned against human (hg19 genome, Ensemble v75 transcriptome) or
KSHV (NC_009333) genomes and transcriptomes using the bowtie2 algorithm, and RSEM
v1.2.31 software was used to estimate read counts and FPKM values at the gene level [48, 49].
Raw counts were converted to log2 (5+count) values and quantile normalized to use in Princi-
ple Component Analysis and gene expression heatmaps. Significance and fold change of differ-
ential expression between lesion and control samples was estimated using the DESeq2 method
on raw values and genes with false discovery rate (FDR) <5% were considered as significant
[50]. An additional threshold of 5-fold was used to enumerate a set of most-changed genes
between conditions. Pearson correlation was used to test associations between KSHV tran-
script loads in tissues for significantly differentially expressed genes. Correlations with p<0.05
were considered significant.
KSHV gene functional definitions were obtained from Arias et.al. [51]. Hierarchical cluster-
ing based on the KSHV gene expression was done on the transcripts with at least 10 counts in
at least one sample using Spearman correlation distance for genes and Euclidean distance for
patients using average linkage. The final gene clusters were defined using a distance threshold
of 0.5. Functions were then assigned for each cluster based on the function with the best
enrichment ratio E = % genes in cluster / % genes total. Hierarchical clustering and principal
component analysis was done on z-score converted normalized values using MATLAB
R2016a (v9.0.0). Expression heatmaps were plotted in Microsoft Excel using normalized values
centered versus average across all samples.
Gene set enrichment analysis was done using Qiagen’s Ingenuity Pathway Analysis software
(IPA, QIAGEN Redwood City,www.qiagen.com/ingenuity) using “Upstream Analysis”, “Reg-
ulator Effects” and “Diseases & Functions” options. Activation Z-scores (Z), calculated by IPA
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are a result of combining mRNA expression changes from the experiment and known effect of
the gene on function or upstream regulator on the target (e.g every downregulated gene sup-
pressing a function or upregulated gene activating a function will contribute to predictions as
to whether the function is activated). |Z|>2 predictions were considered significant. Upstream
regulators that were significantly differentially expressed at the mRNA level, had significantly
overrepresented number of known targets (p<10−5) and had a significantly predicted activa-
tion state (|Z|>2) were considered. The only regulator effect network with consistency score
>100 is reported (the next best network had a score of 43). Functions that passed p<10−15
threshold or P<10−5 and |Z|>2 threshold were considered.
For analyzing relationships between genes involved in the lipid and glucose models, Inge-
nuity Knowledgebase was used to derive information for all considered functions. A combined
model was built to demonstrate two aspects: overlap between lipid-related functions, and the
cross-talk of lipid functions with glucose metabolism disorder. Functions that shared 100% of
genes with another function were omitted (e.g. all genes from metabolism and synthesis of
triacylglycerol were in metabolism of acylglycerol and all genes from concentration of acylgly-
cerol were in concentration of lipid). Three of the other 6 lipid-related functions had most,
except for 1 or 2 (>90%) genes as members of a more general function and are depicted in the
model as sub-functions. Information about genes’ effect on each function was considered and
the potential cross-talk is annotated. Genes that did not have a consensus effect on any of the
functions received an “affects” designation. If a gene was known to increase or decrease activity
of any function, it was assigned to one or to both effect categories in cases of both increase and
decrease calls. Additional information includes number of genes specific to the particular
function (not involved in any other considered functions) and the overall number of genes
from the 3 effect categories for all major functions.
CIBERSORT software predictions were based on gene FPKM values using the LM22 cell
signature model in “absolute” mode [52]. Cell abundance was then compared using a two-
sample t-test. Significance was defined at p<0.05.
RNA-seq data from external GEO sets (GSE62829, GSE62344, GSE84237) were processed
as described above and tested for differential gene expression using DESeq2. Microarray data
from external sets (GSE6489, GSE45590, GSE66682) was quantile normalized and log2-trans-
formed before statistical evaluation by one-way ANOVA with correction for multiple testing
to estimate FDR as previously described [53].
The original RNA-seq data from this study was uploaded to the GEO database (https://
www.ncbi.nlm.nih.gov/geo/) with the accession number GSE100684.
RNA-seq validation with real time-PCR
To verify the RNA transcript level changes observed from the transcriptomic profiling data, a
two-step qRT-PCR methods was used to measure the RNA transcript level for selected host
genes. First, DNase I-treated total RNA extracted from the tissues was subjected to cDNA syn-
thesis using Superscript III reverse transcriptase primed with random 9-nonamers (Invitrogen,
Waltham, MA). The amount of cDNA was measured with Qubit ssDNA assay kit (Invitrogen,
Waltham, MA). Real-time PCR reactions were prepared using iQ™ SYBR Green supermix
(Biorad, Hercules, CA). Each PCR reaction contained 20 ng of cDNA with primer pairs for the
respective host genes (S1 Table). qRT-PCR was performed in a QuantStudio3 instrument
(Applied Biosystems, Waltham, MA) under the following cycling parameters: 50˚C for 2 min,
95˚C for 10 min; 40 cycles at 95˚C for 15 sec and 60˚C for 1 min; followed by melt-curve
parameters: 95˚C for 15 sec, 60˚C for 1 min, 95˚C for 15 sec. Lesion tissues were measured in
triplicate, while normal tissues were measured in duplicate due to reduced cDNA yield.
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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard for
each target gene. The RNA transcript level was presented as relative quantification (RQ) using
the comparative cycle threshold (ΔΔCT) method. Briefly, the ΔCT for each target gene was cal-
culated by subtracting the CT for GAPDH in the same sample from the CT for target gene.
For each target gene, their respective average ΔCT from the normal tissue was used as a ref-
erence for the calculation of ΔΔCT by subtracting ΔCT for normal tissue from the ΔCT for
lesion tissue. Finally, the RQ for each target gene is defined as 2- ΔΔCT.
Results
Demographic of epidemic KS patients
Four male HIV-1 positive epidemic KS patients 37 to 54 years of age were recruited from Zam-
bia and Tanzania. Two of the four patients (p32 and p83) had been on ART for over 2 years at
the time of inclusion in the study. The other patients (p22 and p23) had received ART for 2 to
3 months (Table 1). All patients were fully suppressed with undetectable HIV-1 plasma viral
load. However, KSHV viral DNA was detected in the plasma of three out of four patients.
Quantification of KSHV load in the extracted lesion tissue DNA revealed 1.14x105 and
8.17x105 copies/million cells in the long-term ART treated patients (p32 and p83 respectively),
while the recently ART treated patients (p22 and p23) had a lower KSHV load at 6.93x103 and
5.44x104 copies/million cells. The extracted RNAs from lesions and control tissues were used
for subsequent RNA-seq analysis.
RNA-seq and analysis
The RNA extracted from the lesion and control tissues were sequenced at a depth of over 12
million reads/sample (Table 2). After passing the standard quality control, reads with good
quality scores, were aligned against the reference human and KSHV genomes and transcrip-
tomes (Fig 1). The majority of reads aligned to the human transcriptome, with at least 79%
Table 1. Patient demographic information.
Patient ID Country Sex Age HIV status ART duration (months) Plasma HIV load Plasma KSHV load Lesion KSHV DNA load (copies/106 cells)
p22 Zambia M 46 + 3 - + 5.44 x 104
p23 Zambia M 40 + 2 - + 6.93 x 103
p32 Zambia M 37 + 60 - + 1.14 x 105
p83 Tanzania M 54 + 24 - - 8.17 x 105
Legends: M = Male; + = detectable;— = undetectable
https://doi.org/10.1371/journal.ppat.1006844.t001
Table 2. RNA-seq raw reads and alignment statistics.
Class Patient ID Total reads Aligned Human Transcriptome Aligned KSHV Transcriptome
Lesion p22 15,471,116 12,849,035 (83%) 1,650
p23 12,060,351 10,225,520 (85%) 17,202
p32 15,907,935 12,629,009 (79%) 718
p83 15,947,529 13,198,922 (83%) 3,441
Control p22 13,818,393 10,543,129 (76%) 2
p23 14,040,685 10,745,704 (77%) 0
p32 14,307,950 10,240,092 (72%) 0
p83 14,653,312 10,872,584 (74%) 60
https://doi.org/10.1371/journal.ppat.1006844.t002
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and 72% alignment rate for the lesion and control tissues, respectively. As expected, there were
more reads aligned to the KSHV transcriptome in KS lesions, (range 718–17202 reads) com-
pared to control tissues (range 0–60 reads) (Table 2). Although low KSHV transcripts reads
were detected in some control tissues, it represent less than 2% of the viral reads detected in
the corresponding KS lesion and likely originated from the KSHV positive circulating periph-
eral blood mononuclear cells (PBMC). After normalization to the total number of aligned
reads, the KSHV RNA load within each tissue was estimated from the total read count aligned
to the KSHV transcriptome. Gene expression profiles for both human and KSHV transcrip-
tome were then determined for both the lesion and control tissues, as well as in correlation
with the KSHV RNA load in the lesion. Genes that were demonstrated to be significantly up or
downregulated were then selected for upstream regulator, functional and pathway analyses to
explore potential mechanisms dysregulated by KSHV in KS lesions. Finally, genes that were
differentially expressed in the lesions were comparatively overlapped with other published
KSHV microarray or RNA-seq datasets.
KSHV gene expression profile diversity in individual lesions
Alignment of the KSHV gene expression profile in the lesion and control tissues to the refer-
ence KSHV genome and transcriptome showed that nearly no KSHV expression was detected
in the control tissues, except in patient p83, where 60 reads in the control tissue aligned to the
KSHV transcriptome (Fig 2A). In contrast, robust KSHV gene expression was readily detected
in all lesion tissues. Twenty viral genes were expressed at levels 6-fold than in the control tis-
sues. These differences were statistically significant with a false discovery rate (FDR) of 5%
with additional 15 genes passing nominal p 0.05 (Fig 2A). Other viral genes were also
detected in the lesion tissues, but differentials did not reach significance (Fig 2B). Lack of sta-
tistical significance is a result of variant levels of expression of these viral genes among the four
lesion samples. For example, K5 and vIRF3 gene expression was clearly highly upregulated in
the lesion tissue of patient p23 compare to its corresponding control tissue, yet the significance
of this difference is masked by the relatively low expression of the same gene in lesions from
the other three patients.
Next, we explored how the differences in viral gene expressions relate to their known or
presumed functions. Viral genes were classified based on the functional categories of latency,
expression and replication, structural proteins, immunomodulation and undefined functions.
Normalized expression of genes showing at least 10 aligned reads was used for hierarchical
clustering. The analysis yielded 6 major clusters of genes showing distinct patterns among the
four patients (Fig 2C). While all lesions tissues expressed latency genes at high levels, patients
Fig 1. Schematic of RNA-seq analysis work flow.
https://doi.org/10.1371/journal.ppat.1006844.g001
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Fig 2. Expression and functional classification of KSHV genes. (A) KSHV genes significantly upregulated in the lesions
(p<0.05). (B) Other KSHV genes detected in the lesions. (C) Clustering of genes and patients based on KSHV genes with
10 reads in at least one sample. Each cluster with5 genes was then annotated with the most enriched function.
https://doi.org/10.1371/journal.ppat.1006844.g002
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p83 and p23 had relatively higher expression of those genes (cluster 4). Relative expression in
the lesion tissues from patients p22 and p23 was higher for genes from the expression and rep-
lication categories (clusters 2, 3). KSHV structural clusters was defined by upregulation in
patients p22 and p23 (cluster 1) and patients p23 and p32 (cluster 6), suggesting a higher level
of lytic replication in tissue. Immunomodulation related genes were expressed in all patients,
with patient p23 displaying the highest expression level (cluster 5).
Parallel human gene expression profile among epidemic KS lesions
After alignment to human transcriptome, relationships between sample were studied by Prin-
ciple Component Analysis which indicated 40% and 17% sample variability (the first and sec-
ond principal component, respectively) (Fig 3A). We note that the first principal component
mainly corresponds to the KSHV RNA load within the tissue. While the lesion and control
tissues formed distinct clusters, the control tissues shows less variability. In addition, control
tissue from patient p83 is unique as it associates more closely to the lesion tissues. This associa-
tion is likely due to the presence of low KSHV RNA level in this control tissue, resulting in
marginally similar transcriptional profile to those of lesion samples.
Direct comparison of gene expression between the collective lesion and control samples,
revealed 3589 significantly differentially expressed genes (FDR< 5%), 1096 of which have 5
fold changes (Fig 3B) and 52 genes showing 20-fold change (Fig 3C). A comparison of gene
expressions among the 4 lesion/control tissue pairs is shown in S2 Table, demonstrating the
highly similar expression pattern among the samples. Expression heatmap for the top 30
known most changed genes, regardless of their correlation with KSHV RNA load within the
tissues, are shown for each tissue sample in S1 Fig. In addition, 311 genes in the lesion tissues
were both significantly differentially expressed (FDR< 5%) and directly correlated with the
KSHV RNA load within the tissues (p< 0.05) with top 30 genes shown in Fig 4.
Verification of cellular gene expression by real time-PCR
A subset of the gene expression results determined by the RNA-seq analysis were validated by
real-time PCR. Six cellular genes, 4 upregulated and 2 downregulated genes, from the lesion
tissues were selected. These genes were distributed across the range of expression changes
between lesion and control tissues and each target was strongly correlated with KSHV RNA
load in the tissues. The up or downregulation expression of these genes as quantified by real
time-PCR was concordant with the results obtained through RNA-seq analysis. Patient p23
displayed the highest fold increases in the expression of the 4 upregulated genes examined (Fig
5A). A similar pattern was observed among the downregulated genes, where the patient p23
has evinced the highest fold decreases (Fig 5B). Together, these results confirmed the validity
of the gene expression profiles determined from RNA-seq analysis.
Predicted transcriptional regulator network in KS lesions
Given the profound changes in gene expression profiles observed in KS tissues, the levels of
transcriptional regulators for these genes may have been altered and could impact downstream
biological processes. To investigate this issue, we tested the set of genes that were significantly
differentially expressed in the lesions for enrichment of known key transcriptional regulators
using the Upstream Regulator Analysis within the Ingenuity Pathway Analysis (IPA). IPA
Knowledgebase contains information about known regulators targets and can predict which
transcriptional regulators are responsible for certain biological processes or it can suggest
pathways and the potential impact regulators may have on those pathways. Our analysis identi-
fied 5 genes upregulated in lesion tissues with a significant number of their targets (p<10−5)
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Fig 3. Cellular gene expression. (A) Relationship between the samples based on cellular gene expression using the Principal Component (PC)
analysis. Combination of the first and the second PC coincided with the KSHV RNA load, indicating that KSHV genes expression affected the cellular
gene expression. (B) Number of cellular genes significantly (FDR<5%) differentially upregulated (red) or downregulated (blue) in the lesion vs control
samples, expressed in fold changes. (C) Significantly differentially expressed cellular genes and their raw expression (maximum raw read count across
samples). All cellular genes with20 fold change are highlighted with yellow dots and genes selected for real time-PCR validation are highlighted with
green dots.
https://doi.org/10.1371/journal.ppat.1006844.g003
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changed in a direction which indicates an activated regulator status on a protein level (positive
Z-score>2) (Fig 6A). The top activated regulator was the tumor growth factor beta-1
(TGFB1), which potentially regulates the expression or function of 399 different genes and
plays an important role in various immune responses such as regulation of B cells [54].
Fig 4. Heat map showing the relative expression of cellular genes with the highest fold changes between the lesion
and controls. Top 30 most differentially expressed cellular genes that were also significantly correlated with the KSHV
RNA load in the lesions. Green circle indicates genes selected for real time-PCR validation.
https://doi.org/10.1371/journal.ppat.1006844.g004
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Fig 5. Validation of selected cellular gene expression by real time-PCR. (A) Upregulated genes, ITGA9, ADAM19, PALD1 and TIE1 in the lesion relative
to the control tissues. (B) Downregulated genes, CRYAB and ADIPOQ in the lesion relative to the control tissues.
https://doi.org/10.1371/journal.ppat.1006844.g005
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Fig 6. Upstream regulators significantly affected in the lesions. (A) List of known regulators that demonstrated
significant expression changes and affected the expression of its known downstream target genes. “pv” = p-value, “n” =
number of known target genes changed in lesions, “fold” = expression changes for the regulator, “Z” = z-score for the
predicted change of the regulator activity. (B) Top regulator network discovered by Ingenuity Pathway analysis with
IFNA predicted to be activated, resulting in expression changes of the CXCL9, 10 and 11 that mainly activate multiple
blood-related functions.
https://doi.org/10.1371/journal.ppat.1006844.g006
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Another 8 potential regulators with decreased expression showed a negative Z-score, indicat-
ing an inhibited status (Fig 6A). The most inhibited regulator was adiponectin (ADIPOQ),
which affects 45 different genes involved in various metabolic pathways.
In order to find other regulators that may impact downstream pathways, we screened the
data set with the IPA Regulator Effects analysis. The top scored regulator effect network was
the interferon alpha network that drives activation of blood-cell related functions, such as cel-
lular adhesion, extravasation and recruitment of leukocytes, suggesting tissues are producing
signals to promote increased infiltration of immune cells into the lesions (Fig 6B).
Gene expression profile associations with disease and biological function
To better understand which diseases or biological functions were the most correlated with the
observed gene expression profiles, we focused our analysis on 884 genes that have at least
5-fold expression changes in the lesion relative to control tissue. As indicated by their p-values,
the top 7 functions impacted by KS altered gene expression were all related to cancer. However,
we cannot determine if these functions were increased or decreased due to lack of information
in the IPA (Fig 7A). More importantly, 4 functions that showed increased activities (Z-Score >
2) were closely associated with cancer (Fig 7A). In addition, another 115 genes associated with
glucose metabolism disorder had increased activities (p = 7x10-13, Z-Score = 2.28). Among the
significantly enriched functions that showed decreased activities in the lesion tissues, 8 lipid
metabolism functions and 7 functions related to small molecule biochemistry were revealed.
These analysis suggested that fundamental glucose and lipid metabolic pathways are substan-
tially altered in the KS lesions.
To further illuminate the relationship of genes involved in the lipid and glucose metabolism
in the lesion, the Ingenuity Knowledgebase was used to derive information for all considered
functions. Significant downregulation of 49 of 67 genes (73%) with overlap between the 6 lip-
ids functions was noted (Fig 7B, S3 Table). In contrast, the downregulation of genes involved
in the glucose pathway associate with increased activity of glucose metabolism disorder, which
in turn, could both increase or decrease the activity of the lipid metabolism.
Cell infiltration into lesion tissues
One of the roles for immune cells is to surveil against foreign antigens, however, such surveil-
lance, if present, clearly did not prevent the development of KS lesions in these evaluated cases.
To test the hypothesis that failure of immune cells to target and infiltrate tumor tissue contrib-
uted to KS, we interrogated the cellular gene expression dataset with the CIBERSORT software
to estimate the proportions of immune cells in tissues. We found that the levels of B cells, mac-
rophages and NK cells in lesions were predicted to be significantly higher than in control tis-
sues (p = 0.004, p = 0.019 and p = 0.048, respectively), and mast cells were lower (p = 0.036)
(Fig 8). T cell infiltration into the lesions was only predicted in 3 of 4 patients, and gene signa-
tures associated with dendritic cell infiltration was only detected in lesions from patients p32
and p83, but were not higher than in control tissues. These results are congruent with the regu-
lator effect prediction above that suggested KS tumors were producing chemo-attractants to
promote infiltration of immune cells.
Similarity between in-vitro studies and actual lesion tissues
Since most of the available KS or KSHV infection gene expression data has been derived
from in vitro experiments in cell lines, we investigated the overlap of our in vivo lesion tran-
scriptomes with these dataset derived from model systems (S4 Table). Gene expression data
from 7 published studies were analyzed [41–47]. Only 3 of the 7 showed significant overlap
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Fig 7. Predicted disease and biological functions associated with cellular gene expression. (A) Enrichment analysis for
functions significantly affected in the lesions based on5 fold of gene expression changes. Top functions with significantly
predicted activation state (p<10−5, |Z|>2) are shown. “pv” = p-value, “n” = number of known target genes changed in
lesions, “Z” = z-score for the predicted change of activity, “ns” = unassigned. (B) Significantly changed genes involved in
overlapping lipid-related functions and/or glucose metabolism disorder in lesions are shown. Small squares indicate
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with our data. Despite variability in the cell types employed in those 3 studies, our analysis
indicated that 688 genes overlapped between our KS lesion dataset and these in vitro models
(Fig 9A), with 38 overlapping genes having similar expression pattern among all 4 studies
(Fig 9B). The KSHV infected TIME cells showed the highest similarity to lesions with 545
overlapped genes, followed by the LEC and HMVEC cells with 232 and 124 overlapped
genes, respectively (Fig 9A). Some of these overlapped genes included, for example, a disinte-
grin and metalloprotease domain 19 (ADAM19) whose expression also correlated with
significantly enriched sub-functions that share>90% of genes with major functions (big squares). Top portion of the figure
(above the grey line) represent overlap between various lipid functions, while the bottom portion (below the grey line)
illustrates cross-talk with glucose metabolism disorder. The hexagons beside major functions indicate the number of genes
contributing to that function’s activation (red), inhibition (blue) or unspecified effect (gray). The brown circles beside major
functions indicate the number of genes which belong exclusively to that major function. Circles indicate genes shared
between at least 2 functions that are up-regulated (red) or down-regulated (blue). Gene involvements are shown by solid and
dotted lines (red for increased activity, blue for decreased activity, black for unspecific activity) and by small circles attached
to a given gene with color matched to the color of square representing the corresponding function. Illustrative example:
Concentration of lipid (green big square) in the center of the figure is repressed in lesion (blue font), as evidenced by 44
genes suppressing that function in lesions (blue hexagon), while only 21 genes activate the function (red hexagon) and 17
genes affect it in an unspecified direction (gray hexagon). Out of these 82 genes, there are 23 unique genes (brown circle)
specific to this function and the rest are shared with at least one other function. Green line link with the upper left group of
genes that are shared with fatty acid metabolism. Green line link with the upper right group of genes that are shared with
synthesis of lipid. Green line in the middle link to the group of genes that are shared between the three major lipid functions
(Fatty acid metabolism, concentration of lipid and synthesis of lipid). ADIPOQ (locates at the bottom of the middle group of
genes) is a gene shared between these three major lipid functions. It is also involved in the metabolism of acylglycerol
(attached small yellow circle), storage of lipid (attached small dark green circle) and glucose metabolism disorder (center
small cyan circle). Given its involvement in glucose metabolism disorder, ADIPOQ is also shown in the bottom portion of
the figure where the attached small circles illustrate its involvement in the three major lipid functions. Its location in the red
group of genes at the lower left is indicative of genes whose changes result in activation of the function (red arrow). Given
that ADIPOQ is represented by a blue circle (down-regulated genes in lesions), it means that the downregulation of
ADIPOQ in lesion results in activation of glucose metabolism disorder. Finally, ADIPOQ is among the genes that suppress
one lipid function (blue dotted line with ┬) and activate another (red dotted line with arrow).
https://doi.org/10.1371/journal.ppat.1006844.g007
Fig 8. Estimated differences in the blood cell populations between the lesion and control tissues. Blood cell abundance was estimated by
CIBERSORT from the gene expression and compared between the lesion and control tissues. Significant p-values are highlighted in red for the
increased and in blue for the decreased blood cell abundance in the lesion.  denote statistical significant in comparison to the controls.
https://doi.org/10.1371/journal.ppat.1006844.g008
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Fig 9. Gene overlap with other studies. (A) Venn diagram showing the number of overlapped genes that were significantly differentially
expressed between the KS lesion and 3 other in vitro studies. Only genes with expression changes at FDR<5% in the same direction (lesion vs
control or infected vs non-infected cells) were considered an overlap. (B) List of the 38 overlapped genes among the 4 studies. Lesion/control
and infected/non-infected fold changes are shown. Red indicate up-regulation. Blue indicate down-regulation. (C) Genes overlapped with at
least one study and are also involved in significantly enriched lipid and glucose functions.
https://doi.org/10.1371/journal.ppat.1006844.g009
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KSHV RNA load in the lesion. In addition, the predicted upstream regulator erythroblast
transformation-specific related gene (ERG) and one of the downstream affected genes
C-X-C motif chemokine 11 (CXCL11) were also upregulated in in vitro models. Moreover,
some of the overlapping genes among the studies also shared similar enriched functions,
especially in glucose metabolism disorder and lipid functions (Fig 9C and S5 Table). How-
ever, overlapped genes represented only ~19% of the significantly differentially expressed
genes in the lesion. The disparity in the gene expression profiles is likely due to the homoge-
neous nature of infected cell lines, whereas the lesion represented a much more complex, but
realistic environment where multiple cell types co-exist and interact with direct and indirect
effects of KSHV infection on cellular transcription.
Discussion
This study is the first to profile the expression of KSHV and the cellular genes in the tumor
microenvironment utilizing high-throughput RNA sequencing. Our data derived from
lesion and contralateral control tissue biopsies of African epidemic KS patients showed a
desultory pattern of KSHV gene expression in the tumor tissue between the patients. This is
likely due to the multi-cellular lineage composition of the lesions, where diverse cell types in
various stages of KSHV infection co-exist. However, we did find that the most dominantly
expressed KSHV genes in all the lesions were involved in the establishment and maintenance
of latency or in immune modulation. The high expression of viral immune modulation
genes such as K2 (viral interleukin-6), K5 (modulator of immune recognition), K7 (viral
inhibitor of apoptosis) and ORF75 (degradation of ND10 protein) in the lesions, could have
severely hindered the immune system from eliminating these KSHV infected cells and con-
tributed to the development of cancer. The upregulation of K2 in our data is consistent with
a previous KS lesion gene expression study using real time-PCR [55]. In contrast to a prior
report suggesting the potential oncogenic properties of the viral genes K1, ORF74 and
vIRF1, we detected very few reads for these genes (ranged from 1 to 8 reads) in tumor tissues,
suggesting either a very limited role of these genes in KS neoplastic growth or that their func-
tion is only essential at a temporally earlier stage in tumor development [56]. In addition,
lytic gene expression was robust in the rapidly expanding cancer cells for two patients, p22
and p23 but restricted the other two patients. This observation is reminiscent of the limited
sporadic lytic replication in various cell lines experimentally infected with KSHV, suggesting
that sustained growth of KSHV transformed cells does not require robust lytic replication
[57].
Interestingly, we found that patients with longer exposure to ART tended to have lower
KSHV viral gene expression in their lesion and vice versa. For example, the patient p32
received ART for 60 months and had the least number of reads aligned to KSHV. The low
viral gene expression also had a moderate inverse-correlation (r = −0.56) with higher lesion
KSHV DNA copy number, as determined by real time-PCR. This suggests that prolonged
ART treatment might suppress KSHV viral gene expression, but result in an increase of latent
viral genome as shown by a higher KSHV DNA copy number in the lesions. A potential expla-
nation is that the immune surveillance in these HIV-1 positive individuals improved after pro-
longed ART, effectively suppressing KSHV gene expression. However, a larger sample size will
be needed to confirm these observed relationships.
Our study also revealed that expression of KSHV genes had a tremendous impact on the
cellular gene expression profile. This is illustrated by the significant differences in gene expres-
sion between the lesion and control tissues that demonstrate KSHV mediated global transcrip-
tional reprogramming in the lesion. Despite the disparity in KSHV gene expression, the
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cellular gene expression in the lesions was relatively similar between patients. By analyzing
these common cellular gene changes with the IPA package, several upstream regulator genes
were predicted to be altered in the lesions. These regulators, for example, upregulation of the
transforming growth factor-beta 1 (TGFB1), could potentially impact a series of proteins and
pathways involved in cell proliferation, differentiation and growth. Moreover, our analysis pre-
dicted the activation in lesions of expression of several CXCR3 chemokine ligands, CXCL-9,
CXCL-10 and CXCL-11 that are known to play an important role in the recruitment of
immune cells, and in particular, T cells. Interestingly, these 3 ligands were also reported to be
upregulated in classic KS lesions, suggesting a potential universal phenomenon that is primar-
ily driven by KSHV [58].
In agreement with the prediction of upregulation of CXCR3 chemokine ligands, CIBER-
SORT analysis implicated the lesion contained significant infiltration of various immune cells
such as B cells, macrophages and natural killer cells in all patients. However, dendritic cells
infiltration was predicted only in patients p32 and p83, whereas patients p22 and p23 had over
4-fold decrease than control tissues in apparent dendritic cells infiltration. It is worth noting
that patients p32 and p83 had been on ART for an extended period of time, suggesting that
ART might have stimulated some recovery of innate and adaptive anti-KSHV or anti-tumor
immune response, but still was insufficient to suppress the KS development. The CIBERSORT
also detected no significant infiltration of T cells in tumors, despite the apparent expression of
the CXCR3 T cell chemo-attractants. This brings into question the functionality of the infil-
trating immune cells. It is possible that these immune cells were able to migrate into the lesions
but were incapable of activating their effector functions due to suppression by cytokines,
anergy or checkpoint regulation [59]. Unfortunately, we were not able to confirm or refute
these concepts using the current RNA-seq analyses alone. Transcriptomic, proteomic and
functional assays on separate lineages of tumor-infiltrating lymphocytes with additional sam-
ples will need to be analyzed.
From the unique depth of the cellular transcriptomic data, we were also able to infer which
biological functions in the lesions were most likely to have been affected by the alteration in
cellular gene expression. Intriguingly, beyond a plethora of previously enumerated cancer-
related functions, we discovered profound activation of glucose metabolism disorder, coupled
with significant decreases in multiple lipid anabolic and catabolic pathways. The relationships
between glucose and lipid metabolism in tumor is clearly complex, nevertheless, it is widely
accepted that the Warburg effect, where multiple metabolic processes are altered in the tumor
to sustain the rapid proliferation and expansion of cancerous cells, is common [60]. Our find-
ing of an increased glucose metabolism disorder in KS lesions could be an indication of the
Warburg effect and can be explained by the need for the cancer cells to replicate. Several stud-
ies have shown that KSHV is indeed capable to induce Warburg effect in cell-lines and resulted
in up-regulation of metabolic pathways such as glycolysis [61–64]. Moreover, KSHV latency
genes have been shown to affect glucose metabolism in vitro [65]. However, the decrease in
lipid metabolism activities in these KS lesions is puzzling. Previous in vitro studies have sug-
gested that KSHV requires and activates fatty acid synthesis for survival as latently infected
endothelial cells. Additionally, multiple cellular genes (SCP2, PRDX5, ACSL3, MLYCD,
AGPS, EHHADH, PEX19, PEX12, PEX5 and ABCD3) involved in lipid metabolism were up-
regulated in these in vitro models [47, 66]. Increased lipid metabolism was also observed in
other forms of cancer [67, 68]. Moreover, hypoxia conditions in the core of tumor should have
stimulated lipid synthesis [69, 70]. Surprisingly, we observed a down-regulation of lipid metab-
olism genes in the context of KS lesions. Among the lipid metabolism genes identified in the
previous studies [47, 66], we observed only marginal increased expression for ACSL3, AGPS
and PEX12, the remaining genes were all down-regulated in our KS lesions [47]. Why lipid
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metabolism is not up-regulated, as suggested by in vitro models, in the KS lesions is unclear.
Since KS lesion is a mixture of both normal and tumor cells, it is plausible that we are seeing
an averaging effect with the KSHV-infected tumor cells undergoing up-regulated lipid biosyn-
thesis, whereas the non-tumor cells were down-regulated. Interestingly, it had been reported
that both ART and HIV-1 are capable of inducing lipid dysregulation, which is therefore a
plausible cause for the decreased lipid metabolism observed in these epidemic KS patients
[71–73]. It will be important to analyze the transcriptomes of lesions from HIV-1 negative
endemic KS patients in order to differentiate the impacts due to ART, HIV-1 and KSHV alone
on these metabolic changes.
Given the lack of suitable animal models for KSHV pathogenesis, in vitro cultures have
been the only feasible mechanism to address the effects of KSHV on the infected cells. How-
ever, in vitro systems may not recapitulate the unique and complex microenvironment within
the lesions. By comparing our lesion-based transcriptomic database with several in vitro stud-
ies, we showed that the TIME model reported recently is the most similar in its cellular gene
expression profile to KS tumor biopsies. For example, the downregulation of peroxisome pro-
liferator activated receptor gamma (PPARG) that regulates glucose metabolism and fatty acid
storage was observed in both studies. Nevertheless, only 19% overlap between the lesion tran-
scriptomes and in vitro derived expression repertoires was detected. More than 2901 genes
were uniquely expressed in the lesions but not observed in the KSHV infected cell line models,
suggesting that one needs to be cautious in extrapolating the gene expression data from cell
lines to the human disease.
Finally, although the ipsilateral /contralateral control tissue collected from each KS patient
served as an ideal intra-patient comparator for the lesion, the transcriptomes from these con-
trol tissues may not represent the gene expression profile of a KSHV negative patient. It is pos-
sible that the gene expression of these control tissues was already indirectly or directly altered
by KSHV or by chronic immune responses. Skin tissue from KSHV negative patients will need
to be tested to address this issue. Despite this shortfall, our data provide unique initial insights
into the close relationship between the cellular and KSHV genes in tumorigenesis, as well as
the profound impact of KSHV on numerous cellular regulatory and metabolic pathways that
could potentially be targeted for future treatment of KS patients.
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